ECE-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human ECE-2 (UniProt O60344) expressed in HEK293 cells. Validated for metallopeptidase activity assays, inhibitor IC50 screens, and antibody validation with matched TPB anti-ECE2 (RP-ECE2).
Expression system
HEK293
Cat. #
REC-ECE2

In stock

SKU
REC-ECE2
$498.00

Target Overview

ECE-2 (Endothelin-Converting Enzyme 2; UniProt O60344; EC 3.4.24.71) is a type II integral membrane zinc metallopeptidase belonging to the neprilysin (M13) family. It catalyses the proteolytic processing of big endothelin peptides to generate bioactive endothelins, and has been shown to cleave additional neuropeptide substrates relevant to GPCR signalling. The recombinant human ECE-2 offered here (SKU: REC-ECE2) is produced by transient expression in HEK293 cells, a mammalian system that supports the glycosylation and disulfide-bond formation required for the correctly folded, catalytically active enzyme. HEK293-derived ECE-2 closely approximates the post-translational modifications observed in native human tissue, making it preferable to bacterial or insect-cell preparations for enzymatic and binding studies. In the laboratory, this recombinant is primarily used in three contexts. First, it serves as an active enzyme source for fluorogenic or HPLC-based peptide cleavage assays, enabling kinetic characterisation (Km, kcat, kcat/Km) and inhibitor IC50/Ki determination. Second, it functions as a structurally defined antigen for antibody validation: researchers running Western blot or IHC experiments with the matched Triple Point Biologics anti-ECE2 antibody (RP-ECE2) can use this recombinant as a positive-control standard to confirm band identity and confirm signal specificity. Third, it is used in pull-down and co-immunoprecipitation formats to interrogate protein–protein interactions, including receptor-trafficking complexes. The human species coverage is validated; the HEK293 expression system yields material of defined purity suitable for enzymatic, biophysical, and cell-free reconstitution experiments.

Background

ECE-2 is a member of the M13 family of neutral endopeptidases and shares approximately 59% amino acid sequence identity with the closely related ECE-1. Both enzymes were originally characterised as processing proteases that convert the 38-residue big endothelin precursors into the mature 21-residue endothelin peptides (ET-1, ET-2, ET-3) through cleavage at a conserved Trp-Val bond. ECE-2 is distinguished from ECE-1 by its lower pH optimum (~5.5 versus ~7.0) and its predominant intracellular, perinuclear localisation, suggesting roles in endosomal or late-Golgi peptide processing in addition to cell-surface signalling. Research interest in ECE-2 has broadened considerably beyond endothelin maturation. A 2025 study (Gupta et al., J Pharmacol Exp Ther, PMID 41205376) demonstrated that ECE-2 regulates κ-opioid receptor (KOR) trafficking and functional signalling, placing it at the intersection of neuropeptide processing and GPCR biology. In that work, ECE-2 activity modulated receptor recycling in neuronal model systems — a finding with clear implications for mechanistic studies of opioid receptor desensitisation and resensitisation. Separately, Xiao et al. (Sci Rep, 2025, PMID 39955423) identified ECE-2 signalling through an ET-1/YAP1/MAGEA3 axis in non-small cell lung cancer cell line models, characterising ECE-2 as a potential upstream regulator of transcriptional co-activator pathways studied in oncology research. ECE-2 has also been investigated in the context of neurodegenerative disease research. The homologous ECE-1 has been studied as a candidate modifier in late-onset Alzheimer's disease (Sun et al., Neurobiol Aging, 2023, PMID 37271044), and the broader ECE family is studied for its capacity to degrade amyloidogenic peptides including Aβ, motivating substrate-specificity comparisons between ECE-1 and ECE-2. For researchers designing in vitro experiments, this recombinant ECE-2 is suited to: defining substrate selectivity profiles using synthetic peptide libraries; measuring the effect of phosphoramidon and structurally related metalloprotease inhibitors; and establishing dose–response relationships for candidate small-molecule inhibitors. Researchers using the matched Triple Point Biologics anti-ECE2 antibody (RP-ECE2, validated for Western blot against human ECE-2) can use this recombinant as a calibrated positive-control antigen to confirm antibody specificity and estimate target abundance in cell or tissue lysates. Triple Point Biologics has produced proteinase and inhibitor antibody reagents since 1994, and the recombinant and antibody products are designed to complement each other within a single experimental workflow.

Applications

  • Fluorogenic peptide cleavage activity assay (e.g., big ET-1 substrate conversion monitored by HPLC or fluorescence)
  • Inhibitor IC50 / Ki determination for phosphoramidon-class and candidate small-molecule metalloprotease inhibitors
  • Km and kcat kinetic characterisation of ECE-2 substrate preference across neuropeptide panels
  • Antibody validation positive control on Western blot alongside anti-ECE2 antibody (RP-ECE2)
  • IHC antibody specificity confirmation using recombinant-spiked cell lysate controls
  • Pull-down / co-immunoprecipitation to map ECE-2 protein–protein interactions in receptor-trafficking complexes
  • Cell-free reconstitution of endothelin processing pathway for mechanistic dissection of ET-1/YAP1 signalling axis

References

  1. Gupta A et al. Endothelin-converting enzyme 2 regulates κ opioid receptor trafficking and function. J Pharmacol Exp Ther. 2025. doi:10.1016/j.jpet.2025.103750. PMID: 41205376.
  2. Xiao H et al. Identification of ECE2 signaling in promoting non-small lung cancer progression through ET1/YAP1/MAGEA3 axis. Sci Rep. 2025. doi:10.1038/s41598-025-90159-0. PMID: 39955423.
  3. Shaji A et al. Identification of potential differences in salivary proteomic profiles between estrus and diestrus stage of estrous cycle in dairy cows. Syst Biol Reprod Med. 2024. doi:10.1080/19396368.2024.2370328. PMID: 39008339.
  4. Ling L et al. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/ERK/STAT3 signaling. J Gene Med. 2024. doi:10.1002/jgm.3571. PMID: 37483091.
  5. Sun Z et al. Mutation analysis of the ECE1 gene in late-onset Alzheimer's disease. Neurobiol Aging. 2023. doi:10.1016/j.neurobiolaging.2023.05.002. PMID: 37271044.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant ECE-2 on SDS-PAGE and Western blot?

ECE-2 (UniProt O60344) has a predicted polypeptide MW of ~86 kDa, but the HEK293-expressed recombinant runs at approximately 100–110 kDa under denaturing conditions due to N-linked glycosylation. This glycoform closely mirrors endogenous ECE-2 observed in human brain and placental tissue lysates. When running SDS-PAGE for purity assessment, expect a dominant band in the 100–110 kDa region at >90% purity. If you observe a doublet in this range, this is consistent with differential glycosylation and does not indicate degradation.

What processing form of ECE-2 does this recombinant represent — full-length or ectodomain?

REC-ECE2 represents the catalytically active ectodomain of human ECE-2, comprising the extracellular zinc metallopeptidase domain with the transmembrane anchor absent. This soluble ectodomain format retains the zinc-binding HEXXH motif and disulfide architecture required for activity. It is not the full-length type II integral membrane protein, so it is not suitable for membrane topology or full-length overexpression studies. For enzymatic cleavage assays and antibody validation experiments, the ectodomain form is the functionally relevant preparation.

What substrates does recombinant ECE-2 cleave and what fluorogenic substrate should I use for activity assays?

ECE-2 (EC 3.4.24.71) efficiently cleaves big endothelin-1 at the Trp21–Val22 bond to generate endothelin-1 (ET-1), and also processes big ET-2 and big ET-3. For fluorogenic assays, McaBk2 (Mca-RPPGFSAFK(Dnp)-OH), a bradykinin-based substrate validated for M13-family metallopeptidases, is widely used and gives robust signal at low enzyme concentrations. Substrate concentration of 10–20 µM with 1–5 nM recombinant enzyme in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2) at 37°C provides a linear-range readout suitable for IC50 determination.

What buffer conditions are optimal for recombinant ECE-2 enzymatic activity assays?

REC-ECE2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — a formulation that stabilises the zinc metallopeptidase fold. For activity assays, dilute directly into the same buffer minus glycerol to avoid viscosity effects on fluorescence readings. ECE-2 activity is optimal between pH 5.5–6.8 (lysosomal conditions) in some cellular contexts, but the recombinant ectodomain shows measurable activity at pH 7.0–7.5 in vitro. Include 0.01% BSA as carrier when working at sub-nanomolar enzyme concentrations to prevent surface adsorption losses.

What starting concentration of recombinant ECE-2 should I use for a peptide cleavage or inhibitor IC50 assay?

For fluorogenic McaBk2 substrate assays, a starting enzyme concentration of 2–5 nM REC-ECE2 is recommended at 37°C for a 60-minute endpoint or continuous kinetic read. For HPLC-based big endothelin-1 cleavage assays, 10–20 nM enzyme with 1–5 µM substrate gives sufficient product for UV detection. When running inhibitor IC50 experiments, keep enzyme concentration at or below the Ki of your tightest expected inhibitor (typically ≤10 nM) to avoid stoichiometric titration artefacts. Perform a linearity-of-signal check across 1–50 nM enzyme before committing to a full inhibitor panel.

Can I use REC-ECE2 as a positive control for Western blot with the matched ECE-2 antibody RP-ECE2?

Yes — REC-ECE2 and RP-ECE2 are produced and validated in the same laboratory specifically for this use case. Load 20–50 ng of REC-ECE2 per lane alongside your cell or tissue lysate. The anti-ECE-2 rabbit polyclonal (RP-ECE2) detects the recombinant at the expected 100–110 kDa glycoprotein band, providing an unambiguous size marker for endogenous ECE-2 identification. This pairing is also useful for antibody lot-to-lot consistency checks. See the RP-ECE2 product page (/anti-ece-2-rabbit-polyclonal-antibody) for recommended primary antibody dilutions and validated secondary antibody conditions.

How much recombinant ECE-2 should I load for Western blot positive control and what band should I expect?

Load 20–50 ng of REC-ECE2 per lane for a clean, well-resolved positive control band when using RP-ECE2 as the primary antibody. Expect a band at approximately 100–110 kDa reflecting the glycosylated ectodomain. At 50 ng, the band is clearly visible after standard ECL detection with 1–2 minute exposure; loading >100 ng risks blooming that obscures adjacent lysate lanes. If you are comparing against endogenous ECE-2 in HUVEC or brain tissue lysates, the recombinant and endogenous bands should co-migrate, confirming antibody specificity.

How should I store and handle recombinant ECE-2 to maintain activity, and what is the shelf life?

REC-ECE2 is shipped on dry ice and should be stored at -20°C upon receipt in single-use aliquots to avoid repeated freeze-thaw cycles, which progressively reduce metallopeptidase activity. At -20°C, activity is stable for at least 12 months from the date of manufacture. Once thawed, keep on ice and use within 4–8 hours; do not refreeze. For dilutions below 10 nM, prepare working stocks in assay buffer supplemented with 0.01% BSA immediately before use. Do not store diluted enzyme overnight — the zinc metallopeptidase active site is sensitive to prolonged dilute-solution incubation.

Validation imagery coming soon

Western blot validation figures for REC-ECE2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →